86 related articles for article (PubMed ID: 22399594)
21. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability.
Ward RL; Cheong K; Ku SL; Meagher A; O'Connor T; Hawkins NJ
J Clin Oncol; 2003 Oct; 21(20):3729-36. PubMed ID: 14551292
[TBL] [Abstract][Full Text] [Related]
22. The role of
Hu H; Chen X; Wang C; Jiang Y; Li J; Ying X; Yang Y; Li B; Zhou C; Zhong J; Wu D; Ying J; Duan S
Oncotarget; 2017 Oct; 8(48):84054-84065. PubMed ID: 29137404
[TBL] [Abstract][Full Text] [Related]
23. Promoter hypermethylation of tumor-related genes in peritoneal lavage and the prognosis of patients with colorectal cancer.
Kamiyama H; Noda H; Takata O; Suzuki K; Kawamura Y; Konishi F
J Surg Oncol; 2009 Jul; 100(1):69-74. PubMed ID: 19384904
[TBL] [Abstract][Full Text] [Related]
24. Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas.
Ebert MP; Model F; Mooney S; Hale K; Lograsso J; Tonnes-Priddy L; Hoffmann J; Csepregi A; Röcken C; Molnar B; Schulz HU; Malfertheiner P; Lofton-Day C
Gastroenterology; 2006 Nov; 131(5):1418-30. PubMed ID: 17101318
[TBL] [Abstract][Full Text] [Related]
25. DNA microarray: a high throughput approach for methylation detection.
Gao L; Cheng L; Zhou JN; Zhu BL; Lu ZH
Colloids Surf B Biointerfaces; 2005 Feb; 40(3-4):127-31. PubMed ID: 15708500
[TBL] [Abstract][Full Text] [Related]
26. Detection of aberrant p16 methylation in the serum of colorectal cancer patients.
Zou HZ; Yu BM; Wang ZW; Sun JY; Cang H; Gao F; Li DH; Zhao R; Feng GG; Yi J
Clin Cancer Res; 2002 Jan; 8(1):188-91. PubMed ID: 11801557
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma.
Ribarska T; Ingenwerth M; Goering W; Engers R; Schulz WA
Cancer Genomics Proteomics; 2010; 7(2):51-60. PubMed ID: 20335518
[TBL] [Abstract][Full Text] [Related]
28. MGMT gene is aberrantly methylated from the early stages of colorectal cancers.
Hibi K; Goto T; Mizukami H; Kitamura Y; Sakata M; Saito M; Ishibashi K; Kigawa G; Nemoto H; Sanada Y
Hepatogastroenterology; 2009; 56(96):1642-4. PubMed ID: 20214209
[TBL] [Abstract][Full Text] [Related]
29. Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer.
Miotto E; Sabbioni S; Veronese A; Calin GA; Gullini S; Liboni A; Gramantieri L; Bolondi L; Ferrazzi E; Gafà R; Lanza G; Negrini M
Cancer Res; 2004 Nov; 64(22):8156-9. PubMed ID: 15548679
[TBL] [Abstract][Full Text] [Related]
30. Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles.
de Maat MF; Umetani N; Sunami E; Turner RR; Hoon DS
Mol Cancer Res; 2007 May; 5(5):461-71. PubMed ID: 17510312
[TBL] [Abstract][Full Text] [Related]
31. [Human stool vimentin, oncostatin M receptor and tissue factor pathway inhibitor 2 gene methylation analysis for the detection of colorectal neoplasms].
Zhang JP; Wang J; Gui YL; Zhu QQ; Xu ZW; Li JS
Zhonghua Yi Xue Za Zhi; 2011 Sep; 91(35):2482-4. PubMed ID: 22321844
[TBL] [Abstract][Full Text] [Related]
32. Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas.
Toyooka S; Toyooka KO; Harada K; Miyajima K; Makarla P; Sathyanarayana UG; Yin J; Sato F; Shivapurkar N; Meltzer SJ; Gazdar AF
Cancer Res; 2002 Jun; 62(12):3382-6. PubMed ID: 12067979
[TBL] [Abstract][Full Text] [Related]
33. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer.
Glöckner SC; Dhir M; Yi JM; McGarvey KE; Van Neste L; Louwagie J; Chan TA; Kleeberger W; de Bruïne AP; Smits KM; Khalid-de Bakker CA; Jonkers DM; Stockbrügger RW; Meijer GA; Oort FA; Iacobuzio-Donahue C; Bierau K; Herman JG; Baylin SB; Van Engeland M; Schuebel KE; Ahuja N
Cancer Res; 2009 Jun; 69(11):4691-9. PubMed ID: 19435926
[TBL] [Abstract][Full Text] [Related]
34. Persistence of K-ras mutations in plasma after colorectal tumor resection.
Lindforss U; Zetterquist H; Papadogiannakis N; Olivecrona H
Anticancer Res; 2005; 25(1B):657-61. PubMed ID: 15816642
[TBL] [Abstract][Full Text] [Related]
35. Detection of vimentin (VIM) methylation in the serum of colorectal cancer patients.
Shirahata A; Sakuraba K; Goto T; Saito M; Ishibashi K; Kigawa G; Nemoto H; Hibi K
Anticancer Res; 2010 Dec; 30(12):5015-8. PubMed ID: 21187483
[TBL] [Abstract][Full Text] [Related]
36. TFPI2 and NDRG4 gene promoter methylation analysis in peripheral blood mononuclear cells are novel epigenetic noninvasive biomarkers for colorectal cancer diagnosis.
Bagheri H; Mosallaei M; Bagherpour B; Khosravi S; Salehi AR; Salehi R
J Gene Med; 2020 Aug; 22(8):e3189. PubMed ID: 32196834
[TBL] [Abstract][Full Text] [Related]
37. Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients.
Sun FK; Fan YC; Zhao J; Zhang F; Gao S; Zhao ZH; Sun Q; Wang K
Dig Dis Sci; 2013 Apr; 58(4):1010-5. PubMed ID: 23108564
[TBL] [Abstract][Full Text] [Related]
38. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene.
Chen WD; Han ZJ; Skoletsky J; Olson J; Sah J; Myeroff L; Platzer P; Lu S; Dawson D; Willis J; Pretlow TP; Lutterbaugh J; Kasturi L; Willson JK; Rao JS; Shuber A; Markowitz SD
J Natl Cancer Inst; 2005 Aug; 97(15):1124-32. PubMed ID: 16077070
[TBL] [Abstract][Full Text] [Related]
39. Hypermethylation of the MYOD1 gene is a novel prognostic factor in patients with colorectal cancer.
Hiranuma C; Kawakami K; Oyama K; Ota N; Omura K; Watanabe G
Int J Mol Med; 2004 Mar; 13(3):413-7. PubMed ID: 14767572
[TBL] [Abstract][Full Text] [Related]
40. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma.
Lo Nigro C; Wang H; McHugh A; Lattanzio L; Matin R; Harwood C; Syed N; Hatzimichael E; Briasoulis E; Merlano M; Evans A; Thompson A; Leigh I; Fleming C; Inman GJ; Proby C; Crook T
J Invest Dermatol; 2013 May; 133(5):1278-85. PubMed ID: 23407390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
